Slideset: Hepatitis B Screening, Diagnosis, and Treatment Candidacy
Source: Understanding and Implementing the AASLD’s HBV Practice Guidelines and Other Recent Guidelines and Recommendations on the Diagnosis, Management, and Treatment of Hepatitis B

Slideset

Slideset: Hepatitis B Screening, Diagnosis, and Treatment Candidacy

In this downloadable slideset, Kris V. Kowdley, MD, FACP, FACG, FASGE, AGAF, reviews the latest guideline recommendations on HBV screening, diagnosis, and treatment candidacy.
Format: Microsoft PowerPoint (.ppt)
File size: 5.78 MB
Date posted: 11/11/2010
  • HCV Treatment in Liver Transplantation Recipients: My Take on the Latest HCV Guidance

    Nezam H. Afdhal MD, FRCPI - 4/7/2015    2 comments / Last Comment: 6/3/2015
    In starting HCV treatment after liver transplant, how soon is soon enough?
  • Using Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir in Cirrhotic, Treatment-Experienced GT1 Patients: 12 or 24 Weeks, With or Without Ribavirin?

    Paul Y. Kwo MD - 4/8/2015    4 comments / Last Comment: 8/19/2015
    Until more data are available on the use of the 3-DAA regimen in genotype 1 cirrhotic, treatment-experienced patients, I prefer to err on the side of caution to maximize opportunity for achieving SVR.
  • My Take on New Guidance for Treating Genotype 1 HCV–Infected Patients With Decompensated Cirrhosis

    Norah Terrault MD, MPH - 5/5/2015    3 comments / Last Comment: 7/26/2015
    We now have safe and effective treatment options for HCV infection in patients with decompensated cirrhosis. But how do ribavirin tolerability and treatment experience factor into how they should be used?
  • My Approach to Identifying Treatment Candidates and Maintaining Patients on Long-term HBV Therapy

    Anna S. F. Lok MD - 6/19/2014    9 comments / Last Comment: 1/3/2015
    I find it helpful to discuss the impact of treatment on liver fibrosis/cirrhosis and hepatocellular carcinoma with patients, which motivates some to initiate and adhere to their long-term treatment.
  • Genotype 3 HCV: Still Difficult to Treat?

    Jordan J. Feld MD, MPH - 2/10/2015    1 comment / Last Comment: 2/25/2015
    My take on how to manage genotype 3 HCV and how evolving therapeutic options will likely improve outcomes for treatment-experienced cirrhotic patients with genotype 3 HCV infection.